Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction

Background Trastuzumab is life-extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 ( HER 2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2018-08, Vol.7 (15), p.e008637
Main Authors: Nowsheen, Somaira, Aziz, Khaled, Park, Jae Yoon, Lerman, Amir, Villarraga, Hector R, Ruddy, Kathryn Jean, Herrmann, Joerg
Format: Article
Language:English
Subjects:
breast cancer
cardiomyopathy
cardiotoxicity
chemotherapy
heart failure
HER2
Original Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Trastuzumab is life-extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 ( HER 2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher cardiotoxicity risk than in those with normal cardiac function at baseline. Methods and Results We performed a retrospective study of women treated with trastuzumab for human epidermal growth factor receptor 2 breast cancer at Mayo Clinic Rochester between January 1, 2000 and August 31, 2015 with pre- and on-therapy echocardiograms available for review. A left ventricular ejection fraction (LVEF)
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.118.008637